Teleflex Reports Better Than Expected Q4 Earnings, Issues Mixed FY22 Guidance

Loading...
Loading...

Teleflex Incorporated TFX reported Q4 FY21 revenues of $761.9 million, up 7.1% Y/Y, up 7.9% on a constant currency basis, beating the consensus of $748.63 million.

  • The revenue growth was attributable to higher sales from Anesthesia and Surgical segments.
  • Adjusted diluted EPS increased 10.8% to $3.60, above the consensus of $3.53.
  • The gross margin improved from 53.9% to 55.1%.
  • Guidance: Teleflex expects FY22 revenue growth of 2.3% to 3.8%, equivalent to $2.87 billion - $2.91 billion, versus the consensus of $2.92 billion. 
  • On a constant currency basis, the Company expects full-year 2022 revenue growth of 4.0% to 5.5%.
  • The Company estimates 2022 adjusted EPS of $13.70 to $14.30, +2.8% - 7.3% Y/Y, compared to the consensus of $14.04.
  • The divestiture of the respiratory assets is estimated to be dilutive to 2022 adjusted earnings per share by $0.17.
  • Price Action: TFX shares are trading at $322.34 during the market session on the last check Thursday.
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...